ReviewDigestive diseases and sciences2013
Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation.
Review in Digestive diseases and sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Imaging-based assessment of sarcopenia in liver transplant candidates: A systematic review.World journal of gastroenterology · 2025Pooled it
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.) · 2021Guideline
- ESPEN guideline on clinical nutrition in liver disease.Clinical nutrition (Edinburgh, Scotland) · 2019Guideline
- Muscle weakness, pain, and fatigue impair daily function in chronic kidney disease: a cross-sectional analysis from the I-RACE study.Renal failure · 2026Article
- Psoas Muscle Trajectory and Survival After Liver Transplantation for Steatotic Liver Disease in Severe Obesity.Digestive diseases and sciences · 2026Article
- Impact of physical activity on clinical outcomes in patients with liver cirrhosis: a prospective observational cohort study.Scientific reports · 2026Observational
- The Muscle-Liver Immunometabolic Axis in Liver Transplantation: A Decisive Role in Outcomes and Mechanisms.International journal of biological sciences · 2026Review
- Glucocorticoids trigger muscle-liver crosstalk to attenuate acute liver injury and promote liver regeneration via the FGF6-FGFBP1 axis.Military Medical Research · 2025Article
- Dialysis Duration, Time Interaction, and Visceral Fat Accumulation: A 6-Year Posttransplantation Study.Clinical and experimental nephrology · 2024Article
- Review
- Association of Muscle Mass Loss with Diabetes Development in Liver Transplantation Recipients.Diabetes & metabolism journal · 2024Article
- Newly developed sarcopenia after liver transplantation, determined by a fully automated 3D muscle volume estimation on abdominal CT, can predict post-transplant diabetes mellitus and poor survival outcomes.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- From Listing to Recovery: A Review of Nutritional Status Assessment and Management in Liver Transplant Patients.Nutrients · 2023Review
- Nutritional Strategies to Manage Malnutrition and Sarcopenia following Liver Transplantation: A Narrative Review.Nutrients · 2023Review
- Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management.Clinical and molecular hepatology · 2023Review
- Review
- Frailty in CKD and Transplantation.Kidney international reports · 2021Review
- Sarcopenia in chronic liver disease: mechanisms and countermeasures.American journal of physiology. Gastrointestinal and liver physiology · 2021Review
- Compound Sarcopenia in Hospitalized Patients with Cirrhosis Worsens Outcomes with Increasing Age.Nutrients · 2021Article
- Secondary Malnutrition and Nutritional Intervention in Cholestatic Liver Diseases in Infants.Frontiers in nutrition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Liver transplantation is believed to reverse the clinical and metabolic abnormalities of cirrhosis. Reduced skeletal muscle mass or sarcopenia contributes to increased mortality and adverse consequences of cirrhosis. Failure of reversal of sarcopenia of cirrhosis after liver transplantation is not well recognized. Six temporally, geographically, and methodologically distinct follow-up studies in 304 cirrhotics reported conflicting data on changes in indirect measures of skeletal muscle mass after transplantation. Distinct measures of body composition but not skeletal muscle mass were used and did not focus on the clinical consequences of sarcopenia after transplantation. A number of studies reported an initial rapid postoperative loss of lean mass followed by incomplete recovery with a maximum follow-up of 2 years. Posttransplant sarcopenia may be responsible for metabolic syndrome and impaired quality of life after liver transplantation. Potential reasons for failure to reverse sarcopenia after liver transplantation include use of immunosuppressive agents [mammalian target of rapamycin (mTOR) and calcineurin inhibitors] that impair skeletal muscle growth and protein accretion. Repeated hospitalizations, posttransplant infections, and renal failure also contribute to posttransplant sarcopenia. Finally, recovery from muscle deconditioning is limited by lack of systematic nutritional and physical-activity-based interventions to improve muscle mass. Despite the compelling data on sarcopenia before liver transplantation, the impact of posttransplant sarcopenia on clinical outcomes is not known. There is a compelling need for studies to examine the mechanisms and consequences of sarcopenia post liver transplantation to permit development of therapies to prevent and reverse this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.